In an effort to accurately predict an individual patient’s response after starting or tapering an anti–tumor necrosis factor (anti-TNF) agent, researchers from the Netherlands, reporting findings in Rheumatic and Musculoskeletal Diseases, explain that calprotectin has some predictive value for clinical response in patients starting anti-TNF treatment, although it was not predictive of clinical response after tapering.
While anti—tumor necrosis factor (anti-TNF) agents have revolutionized the treatment of rheumatoid arthritis (RA), not all patients will achieve a good clinical response after 6 months of treatment. Furthermore, while some responders can taper their doses of these agents, not all patients are able to so.
In an effort to accurately predict an individual patient’s response after starting or tapering an anti-TNF agent, researchers from the Netherlands, reporting findings in Rheumatic and Musculoskeletal Diseases, explain that calprotectin has some predictive value for clinical response in patients starting anti-TNF treatment, although it was not predictive of clinical response after tapering.
The researchers obtained baseline serum samples and clinical outcomes of patients with RA who initiated treatment with adalimumab or etanercept by using the Biologic Individual Optimised Treatment Outcome Prediction study, a prospective longitudinal prediction study of patients with RA 18 years or older. Additional data were collected from patients in the dose tapering arm of the Dose Reduction Strategies of Subcutaneous TNF Inhibitors study, which investigated noninferiority of dose reduction in patients stable on adalimumab or etanercept.
Baseline and 6-month serum samples were available for 50 patients initiating adalimumab and 75 patients initiating etanercept. Additionally, 102 patients randomized to taper their dose of adalimumab (n = 38) or etanercept (n = 64) had baseline serum samples available.
In the prospective study, calprotectin levels were weakly to moderately significantly correlated with a disease activity score counted in 28 joints with C-reactive protein (DAS28-CRP), (R = .32; P <.001), erythrocyte sedimentation rate (R = .41; P <.001), and CRP (R = .57; P <.001) at baseline. In the tapering study, calprotectin levels were significantly correlated with CRP (R = .21; P = .03) only.
At 6 months, 50 (40%) of the patients who initiated treatment achieved a good response, measured by European League Against Rheumatism criteria, and baseline calprotectin levels were higher in responders, at 985 ng/mL (range, 558 ng/mL to 1417 ng/mL), than in nonresponders, at 645 ng/mL (range, 415 ng/mL to 973 ng/mL).
Among those who tapered, 47 patients (46%) successfully reduced their dose, 19 (19%) successfully discontinued anti-TNF treatment, and 36 (35%) were unsuccessful at tapering. Calprotectin levels at baseline were similar among all 3 groups.
According to the authors, serum calprotectin has some value for predicting clinical response to anti-TNF agents, although it does not have added value to other clinical factors already used, and it is not a useful predictor for clinical response after tapering therapy.
Reference
Tweehuysen L, den Broeder N, van Herwaarden N. Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis. RMD Open. 2018;4(1):e000654.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys
September 16th 2024Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses the challenges of expanding biosimilars into new therapeutic areas and highlights the role of education, competitive pricing, and integrated delivery networks in improving adoption and market growth.
Real-World Study Shows Comparable Outcomes Between CT-P13, Remicade in RA
September 14th 2024A real-world study of the biosimilar infliximab-dyyb (CT-P13; Inflectra) in rheumatoid arthritis (RA) reported the majority of patients who initiated CT-P13 switched from the reference product (Remicade) or another biologic or targeted synthetic disease-modifying antirheumatic drug.